Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • High-Dose Aspirin...

    High-Dose Aspirin Preferred in Kawasaki disease

    Written by Anjali Nimesh Nimesh Published On 2018-02-17T19:27:30+05:30  |  Updated On 17 Feb 2018 7:27 PM IST
    High-Dose Aspirin Preferred in Kawasaki disease

    Dr. Anita Dhanrajani and associates reviewed charts of patients with Kawasaki disease (KD) from two Canadian centres to assess the impact of ASA dose on IVIG resistance (operationally defined as administration of a second dose of IVIG). Both centres used standard IVIG dosing, but centre 1 used low-dose ASA from diagnosis (3-5 mg/kg/day) while centre 2 used initial high-dose ASA (80-100 mg/kg/day). The researchers found that high dose of Aspirin decreased probability of IVIG re-treatment in Kawasaki disease.


    Kawasaki disease (KD) is an acute childhood vasculitis that may result in coronary aneurysms. Treatment of Kawasaki disease (KD) with a single infusion of 2g/kg intravenous immunoglobulin (IVIG) is well established, but acetyl-salicylic acid (ASA) dose remains controversial.


    In one hospital where low-dose acetylsalicylic acid (ASA; 3 to 5 mg/kg/day) was routinely used, 23% of patients were given a second infusion of IVIG, compared with 8.7% of those treated in another hospital where high-dose ASA (80 to 100 mg/kg/day) was used (P=0.003), according to Anita Dhanrajani, MBBS, of British Columbia Children's Hospital in Vancouver, and colleagues.

    It was found that there were no significant differences in baseline characteristics between the two centres. Re-treatment with a second dose of IVIG was required in 28/122 (23%) patients treated with low-dose ASA, and in 11/127 (8.7%) patients treated with high-dose ASA (p=0.003). After adjusting for confounders, low-dose ASA was associated with higher odds of IVIG resistance (OR=3.2, 95% CI 1.1, 9.1). The mean duration of hospital stay was 4.1 and 4.7 days, respectively (p= 0.37). Coronary artery aneurysms were seen in 2/117 and 6/125 patients from centre 1 and 2, respectively (p= 0.28).



    The authors concluded that low-dose ASA was associated with 3 times higher odds of IVIG re-treatment compared to high-dose ASA, with no significant difference in duration of hospital stay or incidence of coronary artery aneurysms.

    The research findings were reported online in Arthritis Care & Research.





    For more details click on the link :

    Source Reference: Dhanrajani A, et al "Aspirin dose in Kawasaki disease -- the ongoing battle" Arthritis Care Res 2017; DOI:10.1002/acr.23504.

    British Columbia Children's HospitalC-Reactive ProteinKawasaki Diseaseplatelet count

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok